NCT01723748

Somatostatin Analogue Treatment of Acromegaly: Molecular Aspects

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: University of Aarhus · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The treatment with SA still leaves some questions unanswered. Firstly, SA treatment often results in a concomitant suppression of the insulin secretion, which might lead to clinically significant glucose intolerance. Secondly, the traditional evaluation of disease activity by measuring circulating levels of GH and total IGF-I is not reliable enough Hypotheses: Treatment of acromegaly with SA versus surgery alone is associated with: * Glucose intolerance despite normalized insulin sensitivity * Modified peripheral GH activity in peripheral target organs assessed on molecular endpoints

Detailed description

Acromegaly is a rare disease usually caused by a benign growth hormone (GH) producing pituitary adenoma. In case of inadequate disease control, the condition is associated with significant morbidity and approximately a doubling of mortality compared to the background population. Medical treatment with somatostatin analogues (SA) has been employed for about 20 years and is a well-established treatment in cases where surgery is impossible or inadequate. The treatment with SA still leaves some questions unanswered. Firstly, SA treatment often results in a concomitant suppression of the insulin secretion, which might lead to clinically significant glucose intolerance. Secondly, the traditional evaluation of disease activity by measuring circulating levels of GH and total IGF-I is not reliable enough

Conditions

• Acromegaly
• Metabolic Diseases

Interventions

Type	Name	Description
DRUG	genotropin	iii) intravenous exogenous bolus of GH (0.5 mg) followed by muscle and fat biopsies.

Timeline

• Start date: 2012-12-01
• Primary completion: 2015-05-01
• Completion: 2015-05-01
• First posted: 2012-11-08
• Last updated: 2016-04-05

Locations

1 site across 1 country: Denmark